Abstract：
Recent advances in the diagnosis and management of multiple myeloma (MM) have improved patient outcomes. This progress in our understanding of MM has resulted in continuous suppressive therapy concepts, including induction, high dose chemotherapy with autologous stem cell transplantation (ASCT), consolidation, and maintenance therapy. The foundation of maintenance therapy has been with lenalidomide. Other novel immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and targeted monoclonal antibodies have also contributed to this evolution.
This review summarizes the outcomes from phase II/III trials with long-term lenalidomide maintenance therapy alone or in combination with other agents in post-ASCT and non-transplant settings for newly diagnosed patients with MM. We review recent data considering a combination with newer medications and ongoing trials. We also review the optimal duration, MRD negativity rate, and safety and tolerability aspects of lenalidomide maintenance therapy. This review aims to present the current and emerging clinical evidence that supports using lenalidomide as a backbone for maintenance therapy in patients with MM.
There is increasing evidence to support lenalidomide as the backbone of combination therapy in the maintenance setting.
This review summarizes the outcomes from phase II/III trials with long-term lenalidomide maintenance therapy alone or in combination with other agents in post-ASCT and non-transplant settings for newly diagnosed patients with MM. We review recent data considering a combination with newer medications and ongoing trials. We also review the optimal duration, MRD negativity rate, and safety and tolerability aspects of lenalidomide maintenance therapy. This review aims to present the current and emerging clinical evidence that supports using lenalidomide as a backbone for maintenance therapy in patients with MM.
There is increasing evidence to support lenalidomide as the backbone of combination therapy in the maintenance setting.
摘要：
多发性骨髓瘤（MM）的诊断和管理的最新进展改善了患者的预后。我们对MM的理解的这种进展导致了持续的抑制治疗概念，包括归纳法,自体干细胞移植（ASCT）大剂量化疗，合并，和维持治疗。维持治疗的基础是来那度胺。其他新型免疫调节药物（IMiDs），蛋白酶体抑制剂（PIs），靶向单克隆抗体也促成了这一进化。
这篇综述总结了新诊断的MMs患者在ASCT后和非移植环境中单独使用来那度胺长期维持治疗或与其他药物联合使用的II/III期试验的结果。我们回顾了最近的数据，考虑了与新药物和正在进行的试验的组合。我们还回顾了最佳持续时间，MRD阴性率，来那度胺维持治疗的安全性和耐受性方面。这篇综述旨在介绍当前和新兴的临床证据，这些证据支持使用来那度胺作为MM患者维持治疗的骨干。
越来越多的证据支持来那度胺作为维持环境中联合治疗的骨干。
这篇综述总结了新诊断的MMs患者在ASCT后和非移植环境中单独使用来那度胺长期维持治疗或与其他药物联合使用的II/III期试验的结果。我们回顾了最近的数据，考虑了与新药物和正在进行的试验的组合。我们还回顾了最佳持续时间，MRD阴性率，来那度胺维持治疗的安全性和耐受性方面。这篇综述旨在介绍当前和新兴的临床证据，这些证据支持使用来那度胺作为MM患者维持治疗的骨干。
越来越多的证据支持来那度胺作为维持环境中联合治疗的骨干。
